JP2019532633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532633A5 JP2019532633A5 JP2019515405A JP2019515405A JP2019532633A5 JP 2019532633 A5 JP2019532633 A5 JP 2019532633A5 JP 2019515405 A JP2019515405 A JP 2019515405A JP 2019515405 A JP2019515405 A JP 2019515405A JP 2019532633 A5 JP2019532633 A5 JP 2019532633A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022158138A JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16189804.4 | 2016-09-20 | ||
| EP16189804 | 2016-09-20 | ||
| PCT/EP2017/073712 WO2018054940A1 (en) | 2016-09-20 | 2017-09-20 | Diagnostic anti-pd-l1 antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158138A Division JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532633A JP2019532633A (ja) | 2019-11-14 |
| JP2019532633A5 true JP2019532633A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
| JP7525261B2 JP7525261B2 (ja) | 2024-07-30 |
Family
ID=56979447
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515405A Active JP7525261B2 (ja) | 2016-09-20 | 2017-09-20 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
| JP2022158138A Pending JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022158138A Pending JP2023011568A (ja) | 2016-09-20 | 2022-09-30 | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10738120B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3515942B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7525261B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109963872B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017329780B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3037230A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3049875T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL265485B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018054940A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP4541423A3 (en) * | 2016-10-06 | 2025-06-25 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| JP2020522486A (ja) | 2017-06-01 | 2020-07-30 | サイトメックス セラピューティクス インコーポレイテッド | 活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| WO2020151572A1 (en) * | 2019-01-23 | 2020-07-30 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-pd-l1 diabodies and the use thereof |
| CN116400075B (zh) * | 2022-10-14 | 2024-01-05 | 江西烈冰生物科技有限公司 | 检测狼疮性肾炎标志物的试剂及方法 |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| EA037351B8 (ru) * | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| EP2981821B2 (en) * | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| ES2753360T3 (es) * | 2014-05-29 | 2020-04-08 | Spring Bioscience Corp | Anticuerpos contra PD-L1 y usos de los mismos |
| ES2916923T3 (es) | 2014-07-11 | 2022-07-06 | Ventana Med Syst Inc | Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos |
| EP3254110B1 (en) * | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
-
2017
- 2017-09-20 IL IL265485A patent/IL265485B2/en unknown
- 2017-09-20 EP EP17778222.4A patent/EP3515942B1/en active Active
- 2017-09-20 WO PCT/EP2017/073712 patent/WO2018054940A1/en not_active Ceased
- 2017-09-20 JP JP2019515405A patent/JP7525261B2/ja active Active
- 2017-09-20 AU AU2017329780A patent/AU2017329780B2/en active Active
- 2017-09-20 CN CN201780071407.5A patent/CN109963872B/zh active Active
- 2017-09-20 CA CA3037230A patent/CA3037230A1/en active Pending
- 2017-09-20 US US16/334,699 patent/US10738120B2/en active Active
- 2017-09-20 ES ES17778222T patent/ES3049875T3/es active Active
-
2022
- 2022-09-30 JP JP2022158138A patent/JP2023011568A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532633A5 (cg-RX-API-DMAC7.html) | ||
| US11525003B2 (en) | Anti-B7-H3 antibodies and diagnostic uses thereof | |
| US12473354B2 (en) | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| JP7443298B2 (ja) | ヒト成長分化因子１５（ｇｄｆ－１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 | |
| EP3149042B1 (en) | Pd-l1 antibodies and uses thereof | |
| JP6715770B2 (ja) | モノクローナル抗ｔｋ１抗体 | |
| JP2015533788A5 (cg-RX-API-DMAC7.html) | ||
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| EP4010706A1 (en) | Clinical management of oropharyngeal squamous cell carcinoma | |
| RU2016116773A (ru) | Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы | |
| JP2018532699A5 (cg-RX-API-DMAC7.html) | ||
| EP3304086B1 (en) | Method for predicting responsiveness to a combination therapy with lenvatinib and everolimus | |
| WO2020225548A1 (en) | Biomarkers for disease progression in squamous cell carcinoma | |
| US20240026034A1 (en) | Antibodies specific for qsox1 and methods of using the same | |
| WO2009123145A1 (ja) | パラスポリン－１受容体及びその用途 | |
| MX2023008142A (es) | Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y usos de los mismos. | |
| CA3193619A1 (en) | Method for detecting expression or clustering of cell surface moieties | |
| CN104391114A (zh) | Elisa方法定量测定人血清中重组人鼠嵌合抗cd20单克隆抗体浓度 | |
| EA044887B1 (ru) | Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа |